Menu
Start now

Open the Simpledot chat

Best answer, auto-selected

AI workspace online · all systems operational

Daraxonrasib explained: why the cancer drug is trending

Published · 10 sources · 5000+ searches today

Daraxonrasib is trending in the UK after reports on 20 November 2026 described encouraging early results from a trial in advanced pancreatic cancer. The once-daily pill, being tested with chemotherapy, was linked to tumour shrinkage or disappearance in 60.7% of patients, which is why the story has drawn intense attention today.

Key facts

  • 20 November 2026: early trial reports on daraxonrasib were published
  • 61 patients with metastatic pancreatic ductal adenocarcinoma were studied
  • Tumours shrank or disappeared in 60.7% of patients
  • Five patients, or 8.2%, had undetectable tumours on CT scans
  • Median time before tumours returned or grew was 12.8 months

What happened

Reports published on 20 November 2026 said daraxonrasib, a once-daily pill, had encouraging early results when combined with chemotherapy for advanced pancreatic cancer. The study involved patients whose cancer had spread to other parts of the body.

The reported phase 1/2 trial included 61 patients with metastatic pancreatic ductal adenocarcinoma, and the results have been widely shared because pancreatic cancer is so difficult to detect and treat.

What the early results showed

According to the reports, tumours shrank or disappeared in 60.7% of patients treated with daraxonrasib plus chemotherapy. In 8.2% of patients — five people, or roughly one in 12 — tumours were no longer visible on CT scans.

Disease control was reported in 90.2% of participants, but that figure includes people whose disease stabilised rather than disappeared. Another reported analysis said 77% of patients were alive after one year, although the study was still small and early.

Why this is getting attention in the UK

Pancreatic cancer often comes to light late and has long been hard to treat, so reports of tumours vanishing have created a lot of interest. That is why headlines have described the findings as a possible breakthrough and why many people are searching for the drug today.

The study was linked to Revolution Medicines, and Dr Wungki Park of Memorial Sloan Kettering Cancer Center was quoted as being involved in the trial. The findings have raised hopes, but they are not proof of a cure.

What happens next

As of 21 November 2026, daraxonrasib is still an early research treatment rather than an approved cure. Larger controlled trials and longer follow-up are needed to show whether the benefit holds up, what the risks are, and whether regulators will approve it.

The reported median time before tumours returned or began growing was 12.8 months, with follow-up of about 18 months. That is promising, but the evidence is still too limited to say how well the drug will work in routine care.

Frequently asked

What is daraxonrasib?

Daraxonrasib is a once-daily pill being tested with chemotherapy for advanced pancreatic cancer. The reported studies are still early clinical research, not proof of an approved cure.

Why is daraxonrasib trending in the UK today?

Reports published on 20 November 2026 said the drug showed encouraging early results in pancreatic cancer, including tumour shrinkage or disappearance in 60.7% of patients. That has prompted a lot of interest and headlines.

Did daraxonrasib cure pancreatic cancer?

No. The evidence reported so far is from an early study, and it does not show a cure. Larger, controlled trials are still needed to confirm benefits and safety.

What do the 90% and 60.7% figures mean?

The 60.7% figure means tumours shrank or disappeared in that share of patients. The 90.2% figure means disease was controlled, which includes people whose cancer stabilised rather than vanished.

Sources

  1. [1] the-independent.com
  2. [2] bbc.co.uk
  3. [3] telegraph.co.uk
  4. [4] uk.news.yahoo.com
  5. [5] cleveland.com
  6. [6] piqmarkets.com
  7. [7] pharmaphorum.com
  8. [8] markets.businessinsider.com
  9. [9] 10bmnews.com
  10. [10] doctors.net.uk

Researched automatically from live news and written by Simpledot's AI; facts are limited to what the sources above report as of the published time. Spot an error? Tell us.